（文章来源：证券日报） 证券日报网讯 2月3日，银之杰在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东人数 为111848户。 ...

来源：新浪基金∞工作室 电信ETF汇添富（560300）业绩比较基准为中证电信主题指数收益率，管理人为汇添富基金管理股份有 限公司，基金经理为何丽竹，成立（2023-12-05）以来回报为105.17%，近一个月回报为0.12%。 2月3日，电信ETF汇添富（560300）开盘跌0.15%，报2.045元。电信ETF汇添富（560300）重仓股方 面，中国移动开盘涨0.00%，中国联通涨0.62%，中国电信涨0.00%，中国卫通涨1.97%，中际旭创涨 2.71%，银之杰涨0.73%，新易盛涨4.10%，中兴通讯涨1.08%，天孚通信涨5.66%，中天科技涨1.77%。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 ...

来源：新浪基金∞工作室 电信ETF汇添富（560300）业绩比较基准为中证电信主题指数收益率，管理人为汇添富基金管理股份有 限公司，基金经理为何丽竹，成立（2023-12-05）以来回报为110.98%，近一个月回报为3.69%。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 2月2日，电信ETF汇添富（560300）开盘跌0.47%，报2.100元。电信ETF汇添富（560300）重仓股方 面，中国移动开盘跌3.40%，中国联通跌2.35%，中国电信跌3.33%，中国卫通涨0.79%，中际旭创跌 2.16%，银之杰跌0.70%，新易盛涨9.00%，中兴通讯跌0.73%，天孚通信涨0.54%，中天科技涨0.67%。 ...

01． 业绩连续数年亏损，核心业务持续承压 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 1月22日，银之杰（300085.SZ）发布2025年度业绩预告，预计全年归母净利润亏损1.1亿元至1.4亿元， 若最终亏损幅度获财报确认，这将是公司自2021年以来连续第五年陷入亏损。 证券之星注意到，公司2025年第四季度单季亏损较前三季度亏损进一步扩大。与此同时，公司已进 入"无控股股东、无实际控制人"状态，战略决策稳定性面临严峻考验。 从金融IT龙头到亏损"钉子户"，银之杰的发展困局既是传统金融科技企业转型阵痛的缩影，也暴露出公 司在治理、战略与股权层面的深层难题。 1月22日晚间，银之杰发布业绩预告称，预计2025年归母净利润亏损1.4亿元至1.1亿元，去年同期亏损 1.29亿元；预计扣非净利润亏损1.58亿元至1.28亿元，去年同期亏损1.31亿元。 此前在2025年前三季度，银之杰实现收入5.47亿元，归母净利润为-5940万元。因此单看第四季度，估 测公司预计在5060万元至8060万元之间，较第三季度591.66万元的亏损，环比扩大超8.55倍。 对于业绩亏损，银之杰在业绩预 ...

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

格隆汇1月22日丨银之杰(300085.SZ)公布，预计2025年净亏损14,000.00万元～11,000.00万元，扣非净亏 损15,754.44万元～12,754.44万元。2025年度，公司营业收入总体较上年度下降约11.76%，其中，金融 信息技术业务下降约35.94%；移动信息服务业务下降约30.94%；电子商务业务增长约15.49%。2025年 度公司归母净利润为亏损11,000万元至14,000万元，经营业绩亏损的主要原因如下：1、报告期内，公司 金融信息技术、移动信息服务、电子商务三大主营业务合计净利润约为亏损5,908万元至8,908万元，其 中，金融信息技术业务、移动信息服务业务因营业收入下降、计提无形资产减值等原因而呈现亏损；电 子商务业务继续保持盈利且略有增长；2、报告期内，公司因确认2024、2025年度股权激励计划涉及的 股份支付费用合计对公司归母净利润的影响约为-2,740万元；3、报告期内，公司战略投资的东亚前海 证券因2025年度经营亏损对公司投资收益的影响约为-1,560万元；报告期内，公司非经常性损益对归母 净利润的影响金额约为1,754.44万元，上年同期为187.8 ...

Core Viewpoint - The company Silver Zhi Jie (300085.SZ) forecasts a net loss attributable to shareholders of 110 million to 140 million yuan for the fiscal year 2025, indicating a challenging financial outlook [1] Financial Performance - The company's total operating revenue is expected to decline by approximately 11.76% compared to the previous year [1] - The financial information technology segment is projected to experience a significant decrease of about 35.94% [1] - The mobile information services segment is anticipated to decline by approximately 30.94% [1] - Conversely, the e-commerce business is expected to grow by around 15.49% [1] Net Loss Breakdown - The net loss after excluding non-recurring gains and losses is estimated to be between 128 million and 158 million yuan [1]

智通财经APP讯，银之杰(300085.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损 1.1亿元至1.4亿元;扣除非经常性损益后的净亏损1.28亿元至1.58亿元。 2025年度，公司营业收入总体较上年度下降约11.76%，其中，金融信息技术业务下降约35.94%;移动信 息服务业务下降约30.94%;电子商务业务增长约15.49%。 ...

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

Core Viewpoint - The company, Yinzhijie, is forecasting a significant net loss for the year 2025, with expected losses ranging from 110 million to 140 million yuan, primarily due to a decline in revenue across its main business segments [1] Group 1: Financial Performance - The total revenue for 2025 is expected to decrease by approximately 11.76% compared to the previous year [1] - The financial information technology business is projected to decline by about 35.94% [1] - The mobile information services business is anticipated to drop by around 30.94% [1] - The e-commerce business is expected to grow by approximately 15.49% [1] Group 2: Profitability Analysis - The net profit attributable to shareholders is forecasted to be a loss of 110 million to 140 million yuan, with the main reasons being losses in the three core business segments totaling between 59.08 million and 89.08 million yuan [1] - The financial information technology and mobile information services segments are experiencing losses due to declining revenues and impairment of intangible assets [1] - The e-commerce segment continues to be profitable with slight growth [1] Group 3: Additional Financial Impacts - The company will incur a total impact of approximately -27.4 million yuan from share-based payment expenses related to the 2024 and 2025 stock incentive plans [1] - The strategic investment in Dongya Qianhai Securities is expected to negatively impact investment income by about -15.6 million yuan due to operational losses in 2025 [1] - Non-recurring gains and losses are projected to affect net profit by approximately 17.54 million yuan, compared to 1.8785 million yuan in the same period last year [1]